March 24, 2025, 2:56 p.m.
Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech
On Monday, The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) entered into an exclusive license agreement for an obesity drug. Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (exclude...
Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech
On Monday, The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) entered into an exclusive license agreement for an obesity drug. Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excludin…